

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Fiona Harding & David Estell

Serial No.: 09/062,872

Filed: April 15, 1998

For: Mutant Proteins Having Lower Allergenic  
Response in Humans and Methods for  
Constructing, Identifying and Producing  
Such Proteins

Group Art Unit: 1644

Examiner: D. Saunders, Ph.D.

RECEIVED

MAR 20 2001

TECH CENTER 1600/2900

RECEIVED

MAR 13 2001

Technology Center 2100

TRANSMITTAL

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

Enclosed for filing in the above-referenced application please find the following documents:

An Information Disclosure Statement  
PTO 1449 (with disclosed references)

The Commissioner is hereby authorized to charge the fees necessitated by the filing of these documents, or to charge any additional fees under 37 C.F.R. 1.16 and 1.17 or to credit any overpayment, to Deposit Account No. 07-1048.

Respectfully submitted,

*Susan Faris*

Susan K. Faris  
Registration No. 41,739

Date: March 6, 2001

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304  
Tel. (650) 846-7609  
Fax (650) 845-6504

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304  
415/846-7555

TECH CENTER 1600/2900

MAR 08 2001

RECEIVED

pt#24

PATENT  
Docket No. GC527

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Estell et al.

Serial No.: 09/062,872

Filed: April 15, 2000

For: Mutant Proteins having Lower  
Allergenic Response in Humans  
and Methods for Constructing,  
Identifying and Producing such  
Proteins

09/062,872

Group Art Unit: 1644

Examiner: D. Saunders

RECEIVED

MAR 20 2001

TECH CENTER 1600/2900

RECEIVED

3 2001

Technology Center 2100

Information Disclosure Statement

Assistant Director for Patents  
Washington, DC 20231

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) ☐ accompanies the new patent application submitted herewith. 37 CFR §1.97(a).
- (b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) ☐ as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.
- (d) ☒ is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee (\$240) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit

Account No. 07-1048 in the amount of \$240.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in triplicate.

- (e) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in triplicate) to charge Deposit Account No. 07-1048 the fee (\$240) set forth in 37 CFR §1.17(l)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.**

A copy of the items on Form PTO-1449 is supplied:

- ☒ each ☐ none ☐ only those listed below:

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s)

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.